EGFR and non-small cell lung carcinoma: Many large-scale clinical trials have demonstrated that targeted drugs, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), have become a major and preferred treatment modality for advanced NSCLC with EGFR mutations.